Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 113
Filtrar
2.
J Clin Pharm Ther ; 36(6): 704-10, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22023343

RESUMO

WHAT IS KNOWN AND OBJECTIVE: Optimal use of phenobarbital in the neonatal population requires information regarding the drug's pharmacokinetics and the influence of various factors, such as different routes of administration, on the drug's disposition. However, because of sampling restrictions, it is often difficult to perform traditional pharmacokinetic studies in neonates and infants. This study was conducted to establish the role of patient characteristics in estimating doses of phenobarbital for neonates and infants using routine therapeutic drug monitoring data. METHODS: The population pharmacokinetics of phenobarbital was evaluated using 109 serum concentration measurements obtained from routine phenobarbital monitoring of 70 neonates and infants. The data were analysed using the non-linear mixed effects model. A one-compartment pharmacokinetic model with first-order elimination was used. Covariates screened were current total bodyweight (TBW), gestational age, postnatal age (PNA), post-conceptional age, gender and neonates-infants clearance factor (serum concentration of phenobarbital; Conc). RESULTS AND DISCUSSION: The final pharmacokinetic parameters were CL/F (mL/h) = (5.95.TBW (kg) +1.41.PNA (weeks)) Conc (serum phenobarbital concentration >50 µg/mL)(-0.221),Vd/F(L) =1.01.TBW (kg), and F = 0.483 for oral administration and F = 1 was assumed for suppository. Conc(-0.221) is 1 for phenobarbital concentration <50 µg/mL. The important variables for predicting phenobarbital clearance in this study were TBW, PNA and Conc. Phenobarbital clearance increases proportionately with increasing TBW, and an older newborn was expected to have a higher rate of clearance than a younger newborn of equal bodyweight. Moreover, the clearance of phenobarbital decreased nonlinearly with increasing serum concentration of phenobarbital >50 µg/mL (Conc(-0.221) ). WHAT IS NEW AND CONCLUSION: We developed a new model for neonate and infant dosing of phenobarbital with good predictive performance. Clinical application of our model should permit more accurate selection of initial and maintenance doses to achieve target phenobarbital concentrations in Japanese neonates and infants, thereby enabling the clinician to achieve the desired therapeutic effect. A similar approach can be used to validate our model for use in other neonate and infant populations.


Assuntos
Anticonvulsivantes/farmacocinética , Modelos Biológicos , Fenobarbital/farmacocinética , Fatores Etários , Anticonvulsivantes/administração & dosagem , Povo Asiático , Peso Corporal , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos/métodos , Feminino , Humanos , Lactente , Recém-Nascido , Japão , Masculino , Dinâmica não Linear , Fenobarbital/administração & dosagem , Estudos Retrospectivos
3.
J Nutr Health Aging ; 14(8): 716-20, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20922351

RESUMO

OBJECTIVE: Some healthy older adults have difficulty regaining weight after acute weight loss, and the reason for this failure to regain weight is unknown. The objective of this study was to determine if elevated leptin or pro-inflammatory cytokine levels are associated with failure to regain weight over two years after an acute weight loss intervention. DESIGN: Two year prospective study after an acute weight loss intervention. SETTING: University of Washington Medical Center from 2001-2006. PARTICIPANTS: Nineteen older (≥ 70 years old) men and women. MEASUREMENTS: Body weights, health status questionnaire, body composition data, serum leptin, glucose, insulin, C- reactive protein and pro-inflammatory cytokine levels were measured every six months for two years. RESULTS: Five subjects out of 19 failed to regain weight after two years. The subjects who failed to regain weight after 2 years had higher circulating levels of tumor necrosis factor receptor particle 55 (TNFRp55) at baseline and at 6, 12, 18 and 24 months of follow up compared to subjects who regained weight after 2 years (P = 0.02 ). CONCLUSION: Five out of 19 older subjects had difficulty regaining weight for up to 2 years following an acute weight loss intervention, and their TNFRp55 levels were persistently higher than in subjects who regained weight. Greater TNF α action, as reflected by higher circulating levels of TNFRp55, could be contributing towards inability of some older persons to regain weight after acute weight loss.


Assuntos
Receptores Tipo I de Fatores de Necrose Tumoral/sangue , Magreza/sangue , Receptores Chamariz do Fator de Necrose Tumoral/sangue , Redução de Peso/fisiologia , Idoso , Idoso de 80 Anos ou mais , Citocinas/sangue , Dieta Redutora/efeitos adversos , Feminino , Seguimentos , Humanos , Mediadores da Inflamação/sangue , Leptina/sangue , Masculino
4.
Eur Psychiatry ; 25(7): 409-13, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20427155

RESUMO

OBJECTIVE: The objective of this study was to explore factors associated with hara-kiri as a method of suicide and suicidal behavior in contemporary Japan. METHODS: A retrospective study was conducted on medical records of 421 patients (174 male; 247 female) who were considered suicidal and treated at the Kitasato University Hospital Emergency Medical Center in Japan between January 2006 and March 2008. We compared hara-kiri and all other methods regarding sociodemographics and clinical features of all suicidal patients. RESULTS: Instances of hara-kiri suicide attempt had the highest proportion of males (63%) among all suicide and suicidal behavior. One-way analysis of variance revealed significant differences between hara-kiri and other suicide attempt methods in the age of the suicidal patients. Result of multiple logistic regression analysis indicated that those who attempted hara-kiri suicide were likely to be male, be diagnosed with schizophrenia, survive, and be married. CONCLUSION: Our findings indicate that hara-kiri as a method of suicide and suicidal behavior remains prevalent in Japan, and the study findings also suggest that both clinical and cultural factors might play a role in hara-kiri as a method of suicide and suicidal behavior.


Assuntos
Transtornos Mentais/psicologia , Tentativa de Suicídio/psicologia , Suicídio/psicologia , Fatores Etários , Análise de Variância , Feminino , Humanos , Japão , Modelos Logísticos , Masculino , Estado Civil , Prontuários Médicos , Escalas de Graduação Psiquiátrica , Estudos Retrospectivos , Fatores de Risco , Fatores Sexuais
5.
Physiol Res ; 59(1): 97-104, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-19249904

RESUMO

Hyperglycemia is known to cause oxidative stress that leads mainly to enhanced production of mitochondrial reactive oxygen species (ROS). It has been demonstrated that hyperbaric oxygen (HBO) treatment also increases the formation of ROS. There are, however, no comprehensive evaluations of such oxidative effects in diabetes which requires HBO treatment. The purpose of this study is to investigate the influence of a clinically-recommended HBO treatment on glucose homeostasis and oxidative stress in rats with streptozotocin (STZ)-induced diabetes. Under the clinically-used HBO exposure protocol, the levels of blood glucose, thiobarbituric acid reactive substances (TBARS) as a lipid peroxidation marker, and the activity of superoxide dismutase (SOD) as an antioxidant enzyme marker were investigated in the erythrocytes, liver, pancreas, skeletal muscle, and brain of rats with STZ induced diabetes. The levels of blood glucose and TBARS increased significantly (p<0.05), and the activity of SOD decreased significantly (p<0.05) in the erythrocytes and all organs of rats with diabetes subjected to HBO exposure. These results suggested that HBO exposure might boost glucose autoxidation and increase ROS production in STZ-induced diabetes as side-effects of administering HBO treatment for the first time.


Assuntos
Antioxidantes/metabolismo , Diabetes Mellitus Experimental/terapia , Oxigenoterapia Hiperbárica , Peroxidação de Lipídeos , Estresse Oxidativo , Animais , Biomarcadores/sangue , Glicemia/metabolismo , Diabetes Mellitus Experimental/metabolismo , Homeostase , Oxigenoterapia Hiperbárica/efeitos adversos , Masculino , Ratos , Ratos Sprague-Dawley , Espécies Reativas de Oxigênio/metabolismo , Superóxido Dismutase/sangue , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
7.
J Nutr Health Aging ; 12(9): 652-6, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18953464

RESUMO

OBJECTIVES: Involuntary weight loss affects 20% of community dwelling older adults. The underlying mechanism for this disorder is unknown. Objective is to determine if failure of older persons to regain weight is associated with elevated pro-inflammatory cytokine and leptin levels. DESIGN: Prospective diet intervention study. SETTING: University of Washington Medical Center from 2001-2005. PARTICIPANTS: Twenty-one younger (18-35 years old) and nineteen older (>or= 70 years old) men and women. INTERVENTION: Each subject was placed for two weeks on a weight-maintaining diet, followed in sequence by 2 weeks of 30% caloric restriction, then 4 weeks of ad libitum food intake. MEASUREMENTS: Plasma leptin levels, fasting serum pro-inflammatory cytokine levels, and peripheral blood mononuclear cell cytokine levels were measured. RESULTS: Leptin levels in the two cohorts decreased after caloric restriction and increased after ad-libitum food consumption resumed. Plasma TNF alpha levels were higher in older subjects compared to younger adults. However, there was no association between changes in TNF alpha levels and changes in AUC leptin. CONCLUSION: Leptin levels in healthy older individuals responded appropriately in a compensatory manner to changes in body weight. These data do not support a cytokine dependent elevation in leptin levels as being responsible for the failure of older adults to regain weight.


Assuntos
Envelhecimento/sangue , Dieta Redutora , Leptina/sangue , Obesidade/sangue , Obesidade/dietoterapia , Redução de Peso/fisiologia , Adolescente , Adulto , Fatores Etários , Idoso , Envelhecimento/imunologia , Envelhecimento/fisiologia , Área Sob a Curva , Citocinas/sangue , Feminino , Humanos , Masculino , Adulto Jovem
8.
J Clin Pharm Ther ; 32(4): 381-6, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17635340

RESUMO

OBJECTIVE: To establish the role of patient characteristics in estimating doses of digoxin for neonates using routine therapeutic drug monitoring data. METHOD: The steady-state blood level data (n = 129) after repetitive oral administration in 71 hospitalized neonates were analysed using Nonlinear Mixed Effects Modelling (nonmem), a computer program designed for analysing drug pharmacokinetics in study populations through pooling of data. Analysis of the pharmacokinetics of digoxin was accomplished using a one-compartment open pharmacokinetic model. The effect of a variety of developmental and demographic factors on digoxin disposition was investigated. RESULTS: Estimates generated by nonmem indicated that the clearance of digoxin (CL/F; L/h) was influenced by the demographic variables: total body weight (TBW), gestational age (GA) and neonate clearance factor (trough serum concentration of digoxin; Conc). These influences could be modelled by the equation CL/F = 0.0261 x TBW (kg)0.645 x Conc (ng/mL)(-0.724) x GA (weeks)0.8. The interindividual variability in digoxin clearance was modelled with proportional errors. The estimated coefficient of variation was 7.0%, and the residual variability was 13.1%. CONCLUSION: Clinical application of the model to patient care may permit selection of an appropriate initial maintenance dose, thus enabling the clinician to achieve the desired therapeutic effect. However, the digoxin dosage regimen for the individual patient should be based on a careful appraisal of their clinical need for the drug.


Assuntos
Cardiotônicos/farmacocinética , Digoxina/farmacocinética , Monitoramento de Medicamentos , Modelos Biológicos , Peso Corporal , Cardiotônicos/administração & dosagem , Digoxina/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Japão , Masculino , Dinâmica não Linear , Estudos Retrospectivos , Software
9.
Mol Genet Genomics ; 275(4): 367-73, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16435119

RESUMO

The tobacco cultivar Nicotiana tabacum is a natural amphidiploid that is thought to be derived from ancestors of Nicotiana sylvestris and Nicotiana tomentosiformis. To compare these chloroplast genomes, DNA was prepared from isolated chloroplasts from green leaves of N. sylvestris and N. tomentosiformis, and subjected to whole-genome shotgun sequencing. The N. sylvestris chloroplast genome comprises of 155,941 bp and shows identical gene organization with that of N. tabacum, except one ORF. Detailed comparison revealed only seven different sites between N. tabacum and N. sylvestris; three in introns, two in spacer regions and two in coding regions. The chloroplast DNA of N. tomentosiformis is 155,745 bp long and possesses also identical gene organization with that of N. tabacum, except four ORFs and one pseudogene. However, 1,194 sites differ between these two species. Compared with N. tabacum, the nucleotide substitution in the inverted repeat was much lower than that in the single-copy region. The present work confirms that the chloroplast genome from N. tabacum was derived from an ancestor of N. sylvestris, and suggests that the rate of nucleotide substitution of the chloroplast genomes from N. tabacum and N. sylvestris is very low.


Assuntos
Cloroplastos/genética , Genoma de Planta , Nicotiana/genética , Ordem dos Genes , Íntrons , Dados de Sequência Molecular , Fases de Leitura Aberta , Filogenia , Análise de Sequência de DNA , Homologia de Sequência do Ácido Nucleico
10.
J Clin Pharm Ther ; 30(4): 401-5, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15985054

RESUMO

OBJECTIVE: To estimate the population pharmacokinetic parameters of disopyramide using non-linear mixed effects modelling. METHOD: A total of 148 serum levels from 109 patients (61 males and 48 females) receiving disopyramide were collected. RESULTS: The final pharmacokinetic model was Cl (L/h)=3.75.TBW0.567.AGE-0.374.Conc(-0.719).1.48(DOSE>or=5), Vd (L/kg)=4.13 and k(a) (h-1)=0.363, where Cl is total body clearance, Vd is apparent volume of distribution, k(a) is absorption rate constant, TBW is total bodyweight (kg), AGE is age (years), Conc is the concentration of disopyramide (microg/mL), and DOSE>or=5=1 for patient received 5 mg/kg/day of disopyramide dosage or over and 0 otherwise. CONCLUSION: Application of the findings in this study to patient care may permit selection of an appropriate initial maintenance dosage to achieve target disopyramide concentrations and the desired therapeutic effect.


Assuntos
Antiarrítmicos/farmacocinética , Disopiramida/farmacocinética , Modelos Teóricos , Absorção , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Coleta de Dados , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes
11.
J Clin Pharm Ther ; 30(2): 159-63, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15811169

RESUMO

The population pharmacokinetics of phenobarbital was evaluated using 69 serum concentration measurements obtained from the routine phenobarbital monitoring of 35 neonates and infants. The data were analysed using the nonlinear mixed effects model. A one-compartment open pharmacokinetic model with first-order elimination was used. Covariates screened were current bodyweight (TBW), gestational age, postnatal age (PNA), postconceptional age and gender. The final pharmacokinetic parameters were CL/F (mL/h) = 3.41.TBW (kg) + 1.64. PNA (weeks), Vd/F(L) = 1.09.TBW.(kg) [corrected] and F = 0.406 for oral administration and F = 1 for suppository. Application of the findings in this study to patient care may permit selection of an appropriate initial maintenance dosage to achieve target phenobarbital concentrations, thus enabling the clinician to achieve the desired therapeutic effect in neonates and infants.


Assuntos
Ensaios Clínicos como Assunto/métodos , Recém-Nascido/metabolismo , Fenobarbital/farmacocinética , Administração Retal , Envelhecimento/efeitos dos fármacos , Envelhecimento/metabolismo , Disponibilidade Biológica , Peso Corporal/efeitos dos fármacos , Peso Corporal/fisiologia , Feminino , Humanos , Japão/etnologia , Masculino , Taxa de Depuração Metabólica/efeitos dos fármacos , Taxa de Depuração Metabólica/fisiologia , Fenobarbital/administração & dosagem , Fenobarbital/sangue , Estudos Retrospectivos , Supositórios/administração & dosagem , Supositórios/química , Supositórios/farmacocinética
12.
J Clin Pharm Ther ; 28(6): 497-504, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14651674

RESUMO

Non-linear Mixed Effects Modeling (NONMEM) was used to estimate the effects of clonazepam-valproic acid interaction on clearance values using 576 serum levels collected from 317 pediatric and adult epileptic patients (age range, 0.3-32.6 years) during their clinical routine care. Patients received the administration of clonazepam and/or valproic acid. The final model describing clonazepam clearance was CL = 144.0 TBW-0.172 1.14VPA, where CL is total body clearance (mL/kg/h); TBW is total body weight (kg); VPA = 1 for concomitant administration of valproic acid and VPA = zero otherwise. The final model describing valproic acid clearance was CL (mL/kg/h) = 17.2 TBW-0.264 DOSE0.159 0.821CZP 0.896GEN, where DOSE is the daily dose of valproic acid (mg/kg/day); CZP = 1 for concomitant administration of clonazepam and CZP = zero otherwise; GEN = 1 for female and GEN = zero otherwise. Concomitant administration of clonazepam and valproic acid resulted in a 14% increase in clonazepam clearance, and a 17.9% decrease in valproic acid clearance.


Assuntos
Anticonvulsivantes/farmacocinética , Clonazepam/farmacocinética , Ácido Valproico/farmacocinética , Adolescente , Adulto , Anticonvulsivantes/sangue , Anticonvulsivantes/uso terapêutico , Criança , Pré-Escolar , Clonazepam/sangue , Clonazepam/uso terapêutico , Interações Medicamentosas , Feminino , Humanos , Lactente , Japão , Masculino , Taxa de Depuração Metabólica , Modelos Biológicos , Farmacoepidemiologia , Ácido Valproico/sangue , Ácido Valproico/uso terapêutico
13.
Radiat Prot Dosimetry ; 105(1-4): 199-208, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14526956

RESUMO

Regrettably, a criticality accident occurred at a uranium conversion facility in Tokai-mura, Ibaraki, Japan, on 30 September 1999. Radioactivities of 32P in urine, blood and bone samples of the victims, who were severely exposed to neutrons, were measured. 32P was induced in their whole bodies at the moment of the first nuclear release by the reaction 31P (n, gamma) 32P and 32S (n, p) 32P. A realistic biokinetic model was assumed, as the exchange of 32P between the extracellular fluid compartment and the soft tissue compartment occurs only through the intracellular compartment, and the model was used for preliminary calculations. Some acute excretion of 32P, caused by decomposition or elution of tissues which occurred at the time of the accident, may have happened in the victims' bodies in the first few days. The working hypotheses in the present work should initiate renewed discussion of 32P biokinetics.


Assuntos
Osso e Ossos/metabolismo , Modelos Biológicos , Exposição Ocupacional/análise , Radioisótopos de Fósforo/sangue , Radioisótopos de Fósforo/urina , Liberação Nociva de Radioativos , Radiometria/métodos , Cadáver , Simulação por Computador , Humanos , Técnicas In Vitro , Cooperação Internacional , Japão , Taxa de Depuração Metabólica , Nêutrons , Radioisótopos de Fósforo/farmacocinética , Doses de Radiação , Radiometria/normas , Radioisótopos de Rutênio , Sociedades Científicas
14.
J Clin Pharm Ther ; 28(2): 97-101, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12713605

RESUMO

OBJECTIVE: Marked interpatient variability in haloperidol (HAL) level-dose (L/D) ratios makes it difficult to use the administered dose for predicting serum concentrations. OBJECTIVE: To investigate the effect of dose, age, total body weight and co-medication on steady-state HAL L/D ratios. METHOD: Retrospective analysis of dose and HAL blood level data from 168 patients. RESULTS: The HAL L/D ratio decreased curvilinearly with increasing daily dose of HAL. The patients treated with concomitant antiparkinsonian drugs showed a mean HAL L/D ratio that was 24.9% higher than those without antiparkinsonian drugs. The patients treated with concomitant antiepileptic drugs showed a mean HAL L/D ratio that was 27.2% lower than those without antiepileptic drugs. The mean HAL L/D ratio of patients treated with concomitant CYP2D6 substrates was not significantly different from those without CYP2D6 substrates. CONCLUSION: There is a wide interindividual variability in blood levels of HAL in patients given the same dose. Routine monitoring of HAL serum level is useful, especially in patients who require associated antiepileptic and/or antiparkinsonian medication.


Assuntos
Antipsicóticos/sangue , Haloperidol/sangue , Adulto , Idoso , Antipsicóticos/administração & dosagem , Feminino , Haloperidol/administração & dosagem , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
15.
Clin Pharmacokinet ; 40(10): 773-81, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11707062

RESUMO

OBJECTIVE: To clarify the observed variability of digoxin disposition by performing a population pharmacokinetic analysis in a Japanese population. DESIGN: Retrospective analysis of clinical pharmacokinetic data. PATIENTS AND PARTICIPANTS: Data were obtained from 106 patients with heart failure and atrial fibrillation (43 males and 63 females). METHODS: Digoxin concentrations in serum were measured by fluorescence polarisation immunoassay. Population pharmacokinetic analysis was performed using a 2-compartment open pharmacokinetic model with the computer program NONMEM. RESULTS: 246 serum concentrations were obtained. Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise). Concomitant administration of digoxin and spironolactone resulted in a 23% decrease in digoxin clearance. Concomitant administration of digoxin and calcium antagonists (diltiazem, nicardipine, nifedipine or verapamil) resulted in a 21.6% decrease in digoxin clearance. CONCLUSIONS: The estimated population parameter values may assist clinicians in the individualisation of digoxin dosage regimens.


Assuntos
Cardiotônicos/farmacocinética , Digoxina/farmacocinética , Insuficiência Cardíaca/tratamento farmacológico , Modelos Biológicos , Cardiotônicos/sangue , Cardiotônicos/uso terapêutico , Computadores , Digoxina/sangue , Digoxina/uso terapêutico , Feminino , Insuficiência Cardíaca/metabolismo , Humanos , Japão , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Estudos Retrospectivos , Distribuição Tecidual
16.
Gan To Kagaku Ryoho ; 28(11): 1763-7, 2001 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-11708029

RESUMO

A weekly HAI therapy (CPT-11 80 mg, MMC 4 mg, degradable starch microsphere (DSM) 600 mg) was given to a patient with sigmoid colon cancer and multiple liver metastasis (H3) who had been taking tegafur 300 mg/day and 5-FU 750 mg HAI/week, which resulted in PD. This therapy was carried out on an outpatient basis with minimum side effects (< grade 2). After 8 weeks, the tumor marker dropped to one tenth and the liver metastasis decreased in size (PR). The time courses of the concentrations of CPT-11, SN-38 and SN-38G were determined by drawing blood after HAI with or without DSM. The Cmax and AUC inf. of SN-38 at HAI without DSM were 17 ng/ml and 90.55 ng/h/ml, respectively, which was comparable to that at i.v. administration. The Cmax and AUC inf. of SN-38 at HAI with DSM were 12 ng/ml and 129.19 ng/h/ml, respectively, implying that DSM might have an enhancing effect on CPT-11 due to stasis of the hepatic artery that slows the conversion of CPT-11 to SN-38 resulting in a longer existence of SN-38.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Camptotecina/análogos & derivados , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Neoplasias do Colo Sigmoide/patologia , Camptotecina/administração & dosagem , Camptotecina/sangue , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Infusões Intra-Arteriais , Irinotecano , Pessoa de Meia-Idade , Amido/administração & dosagem
17.
J Clin Pharm Ther ; 26(5): 375-9, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11679028

RESUMO

BACKGROUND: In antiepileptic drugs, the marked inter- and intrapatient variability of the level-dose ratio makes it difficult to predict serum concentrations from the administered per kg dose. It is therefore important to identify factors, such as age and comedication, that could contribute to this observed variability. OBJECTIVE: To investigate the effect of age and comedication on clonazepam (CZP) level-dose (L/D) ratios. METHOD: A retrospective evaluation of data from 137 epileptic patients who had received clonazepam. RESULTS: The CZP L/D ratio increased slowly with age up to 15 years in patients on monotherapy. Associated antiepileptic therapy affected the CZP L/D ratio, which was significantly reduced in patients on polytherapy as compared to patients on monotherapy. CONCLUSION: The study therefore suggests that routine monitoring of CZP serum levels is extremely useful, especially in the paediatric age group, and in patients who require associated antiepileptic medication.


Assuntos
Anticonvulsivantes/farmacocinética , Clonazepam/farmacocinética , Epilepsia/tratamento farmacológico , Adolescente , Fatores Etários , Criança , Pré-Escolar , Clonazepam/administração & dosagem , Clonazepam/sangue , Interações Medicamentosas , Quimioterapia Combinada , Epilepsia/sangue , Epilepsia/etnologia , Feminino , Humanos , Lactente , Japão , Masculino , Análise de Regressão , Estudos Retrospectivos
19.
J Nutr Sci Vitaminol (Tokyo) ; 47(3): 181-7, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11575572

RESUMO

Folic acid (folate) levels were measured in the serum of patients with various neurological diseases in Japan. Thirty-six patients showed decreased serum folate levels among 343 consecutive neurological patients (10.5%). Folate administration (15 mg/d) to folate-deficient patients improved neurological symptoms in 24 of 36 cases (67%). Serum folate levels were significantly lower in female than in male folate-deficient patients. Folate-deficient patients showed predominantly axonal neuropathy, which responded to folate supplementation more markedly. Male patients more frequently exhibited neuropathy, especially demyelinating and motor-dominant neuropathy, than females. Anemia was correlated with male sex and low serum folate levels. Male patients were more responsive than females to folate treatment. More male patients had taken excess alcohol or received gastrectomies than females. Neurological symptoms were more frequently improved by folate supplementation in patients with neuropathy than exclusive encephalopathy. Serum folate levels were lower in patients with encephalopathy, especially those with dementia, while folate therapy was more effective in neurological patients without dementia. Dysgeusia and anemia improved in all patients after folate administration. Neurological patients with malabsorption or treated with continuous drip infusion were resistant to folate therapy. Since folate-responsive neuroencepahlopathies are not rare among patients with neurological diseases in Japan, the serum folate level would serve as a valuable indicator for folate supplement therapy.


Assuntos
Deficiência de Ácido Fólico/tratamento farmacológico , Ácido Fólico/sangue , Ácido Fólico/uso terapêutico , Doenças do Sistema Nervoso/sangue , Anemia/sangue , Anemia/complicações , Feminino , Deficiência de Ácido Fólico/sangue , Deficiência de Ácido Fólico/complicações , Hematínicos/administração & dosagem , Hematínicos/sangue , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/complicações , Doenças do Sistema Nervoso/tratamento farmacológico , Fatores Sexuais
20.
J AOAC Int ; 84(4): 1202-8, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11501924

RESUMO

A Certified Reference Material (CRM) was prepared at the National Institute for Environmental Studies (NIES), Japan, in collaboration with the National Institute of Radiological Sciences (NIRS), Japan, for the analytical quality assurance of minor and trace elements in food and related matrixes. The starting material for the CRM was all food served in 29 households in Japan over two 3-day periods in 1997-1998, and thus the CRM represented a typical Japanese diet. All foods (meals, snacks, and beverages) were homogenized, freeze-dried, pulverized, blended, dispensed into 1,100 bottles, and sterilized. The within- and between-bottle homogeneity of the prepared CRM was satisfactory for most of the elements. The concentrations of 14 elements (Na, Mg, K, Ca, Mn, Cu, Zn, As, Se, Sr, Cd, Sn, Ba, and U) were certified based on a collaborative analysis involving NIES, NIRS, and 20 other laboratories. Reference values were given for the concentrations of 12 additional elements (P, Cl, Fe, Co, Ni, Br, Rb, Mo, I, Cs, Pb, and Th). The elements certified and those given reference values include minerals, essential trace elements, contaminant elements, and long-lived radionuclides. Thus, this CRM is of practical value in the quality assurance of element analysis of foods and diets in nutritional, environmental, and radiological research.


Assuntos
Análise de Alimentos , Padrões de Referência , Oligoelementos/análise , Dieta , Humanos , Japão , Controle de Qualidade , Valores de Referência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA